Compare · DXCM vs NPCE
DXCM vs NPCE
Side-by-side comparison of DexCom Inc. (DXCM) and Neuropace Inc. (NPCE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NPCE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 75.5x NPCE ($438.7M).
- Over the past year, DXCM is up 25.7% and NPCE is up 14.0% - DXCM leads by 11.8 points.
- DXCM has hit the wire 6 times in the past 4 weeks while NPCE has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 17 for NPCE).
- Company
- DexCom Inc.
- Neuropace Inc.
- Price
- $86.05-1.93%
- $12.25-3.92%
- Market cap
- $33.10B
- $438.7M
- 1M return
- -2.13%
- -13.73%
- 1Y return
- +25.75%
- +13.95%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 17
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Neuropace Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest NPCE
- CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 335 shares, decreasing direct ownership by 0.65% to 51,357 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Williams Patrick F. covered exercise/tax liability with 1,162 shares, decreasing direct ownership by 2% to 67,508 units (SEC Form 4) (tax liability)
- KeyBanc Capital Markets initiated coverage on NeuroPace with a new price target
- CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,310 shares, decreasing direct ownership by 0.94% to 138,000 units (SEC Form 4) (for tax liability)
- NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
- NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
- CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 0.80% to 139,310 units (SEC Form 4) to satisfy withholding obligation
- CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 358 shares, decreasing direct ownership by 0.69% to 51,692 units (SEC Form 4) (for withholding tax)
- Amendment: SEC Form SCHEDULE 13G/A filed by Neuropace Inc.
- SEC Form 10-Q filed by Neuropace Inc.